Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...

Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Pyxis Oncology (NasdaqGS:PYXS) with a Buy recommendation. Analyst Price Forecast Suggests 474.27% Upside As of ...

Pyxis Tankers Inc. operates as a maritime transportation company with a focus on the tanker and dry-bulk sectors in the United States and internationally. It operates through two segments: Tanker ...

The BSN Pathway is built on a traditional four-year undergraduate curriculum that provides a foundational education that includes both academic and professional nursing courses essential for clinical ...

Pyxis Oncology (PYXS) announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin, a first-in-concept antibody-drug conjugate targeting extradomain-B of ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...